News release
Terumo Aortic is honored to receive the highly prestigious King’s Award for Enterprise in the Innovation category.
This very special award is in recognition of the company’s custom solutions program for treating complex aortic disease (subject to local regulatory approval).
The King’s Awards for Enterprise, previously known as The Queen’s Awards for Enterprise, represent the highest honor for businesses and individuals in the United Kingdom. They are granted to a very small number of UK businesses across all disciplines and recognize outstanding achievement in the fields of innovation, international trade and sustainable development.
This success for Terumo Aortic acknowledges the importance of developing custom device platforms and collaborating with the clinical community by addressing unmet needs. With the highly valued professional expertise and knowledge of both clinicians around the world and our dedicated custom teams, we are driving differentiation with advanced technologies and demonstrating the company’s relentless focus on ‘Commitment to Aortic Care’.
Note: Custom made devices are specifically made in accordance with a written prescription of any person authorized by national law by virtue of that person’s professional qualifications; which gives (1) specific design characteristics provided under that person’s responsibility and (2) is intended for the sole use of a particular patient exclusively to meet their individual conditions and needs. Custom made devices are not available in the US and availability is subject to local regulatory approval.
About Terumo Aortic
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.